<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Medical devices and technologies</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Intuitive sees continued da Vinci growth amid rising competition</title>
      <description>
        <![CDATA[Intuitive Surgical Inc. strengthened its position as the market leader in robotic-assisted surgery in 2025 on the back of increasing demand for minimally invasive procedures. Intuitive’s da Vinci system is seeing robust growth in procedures and installations, fueling increased revenues.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727297</guid>
      <pubDate>Tue, 30 Dec 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727297-intuitive-sees-continued-da-vinci-growth-amid-rising-competition</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/1-24-intuitive-da-vinci-surgeon.webp?t=1602106612" type="image/png" medium="image" fileSize="1745496">
        <media:title type="plain">Surgeon at workstation for surgical robot</media:title>
        <media:description type="plain">Da Vinci surgical system. Credit: Intuitive Surgical Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Korea pharma exports rise to quarterly high of $2.5B in Q1</title>
      <description>
        <![CDATA[South Korea’s pharmaceutical exports rose nearly 18% year-on-year to reach $2.56 billion in the first quarter (Q1) this year, according to the Korea Health Industry Development Institute. Medical device exports, however, dropped about 5% in Q1 2025 to $1.39 billion, attributed to a drop in trade of implant products to both China and the U.S.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721155</guid>
      <pubDate>Tue, 10 Jun 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721155-korea-pharma-exports-rise-to-quarterly-high-of-25b-in-q1</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Asia/South-Korea-flag-business.webp?t=1706306564" type="image/jpeg" medium="image" fileSize="140130">
        <media:title type="plain">Flag of South Korea with skyscrapers in the background </media:title>
      </media:content>
    </item>
    <item>
      <title>Korea pharma exports rise to quarterly high of $2.5B in Q1</title>
      <description>
        <![CDATA[South Korea’s pharmaceutical exports rose nearly 18% year-on-year to reach $2.56 billion in the first quarter (Q1) this year, according to the Korea Health Industry Development Institute. Medical device exports, however, dropped about 5% in Q1 2025 to $1.39 billion, attributed to a drop in trade of implant products to both China and the U.S.]]>
      </description>
      <guid>http://www.bioworld.com/articles/720892</guid>
      <pubDate>Wed, 04 Jun 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/720892-korea-pharma-exports-rise-to-quarterly-high-of-25b-in-q1</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Asia/South-Korea-flag-business.webp?t=1706306564" type="image/jpeg" medium="image" fileSize="140130">
        <media:title type="plain">Flag of South Korea with skyscrapers in the background </media:title>
      </media:content>
    </item>
    <item>
      <title>Durvena strengthens vein grafts to reduce post-surgery failures</title>
      <description>
        <![CDATA[  In what represents the first patenting to emerge in the name of Durvena Inc., co-founder and CEO John Ashley describes the development of a treatment for vein grafts that strengthens the graft and reduces the occurrence of intimal hyperplasia that commonly leads to graft failure.]]>
      </description>
      <guid>http://www.bioworld.com/articles/719620</guid>
      <pubDate>Mon, 05 May 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/719620-durvena-strengthens-vein-grafts-to-reduce-post-surgery-failures</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Durvena-5my25.webp?t=1746480434" type="image/jpeg" medium="image" fileSize="136412">
        <media:title type="plain">Durvena</media:title>
        <media:description type="plain">US20250121118-A1, “Systems, apparatuses, kits, and methods for modification of tissue using a photo-initiator and light.”Assignee: Durvena Inc.Inventors: Buarque, Fernando; Ashley, John; McCormick, MichaelIPC codes: A61F 2/06; A61L 27/36Publication date: Apr. 17, 2025Earliest priority details: US2023544051, Oct. 13, 2023</media:description>
      </media:content>
    </item>
    <item>
      <title>Device makers wary of FDA guidance for AI-enabled software functions</title>
      <description>
        <![CDATA[  The U.S. FDA’s January 2025 draft guidance for AI-enabled device software functions has not fared well in terms of industry response. Two major trade associations argue that the draft is at least somewhat redundant with existing agency guidance.]]>
      </description>
      <guid>http://www.bioworld.com/articles/719384</guid>
      <pubDate>Mon, 21 Apr 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/719384-device-makers-wary-of-fda-guidance-for-ai-enabled-software-functions</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/digital-human-body-with-molecules.webp?t=1729870096" type="image/jpeg" medium="image" fileSize="181884">
        <media:title type="plain">Illustration of human body composed of molecules</media:title>
      </media:content>
    </item>
    <item>
      <title>FDA clears Coris system for cleaning reprocessed endoscopes</title>
      <description>
        <![CDATA[The U.S. FDA gave the green light to Nanosonics Ltd.’s Coris system via de novo clearance for reducing infection risk by delivering improved cleaning outcomes for flexible endoscopes, especially the complex channels of endoscopes that are prone to biofilm build up.]]>
      </description>
      <guid>http://www.bioworld.com/articles/718273</guid>
      <pubDate>Thu, 27 Mar 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/718273-fda-clears-coris-system-for-cleaning-reprocessed-endoscopes</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Nanosonics-Coris-endoscope-reprocessing-platform-27mar25.webp?t=1743106467" type="image/jpeg" medium="image" fileSize="287890">
        <media:title type="plain">Nanosonics Coris endoscope reprocessing platform</media:title>
        <media:description type="plain">Nanosonics Ltd.’s Coris system reduces infection risk by delivering improved cleaning outcomes for flexible endoscopes. Credit: Nanosonics</media:description>
      </media:content>
    </item>
    <item>
      <title>Lent patents pediatric epinephrine auto-injector</title>
      <description>
        <![CDATA[In the first patenting from Lent Innovations LLC, the company’s founder, Anne Lent – an allergist and immunologist – describes their invention of an epinephrine auto-injector tailored to the specific needs of children to reduce the risk of use errors and incorrect injection technique. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/716823</guid>
      <pubDate>Wed, 05 Feb 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/716823-lent-patents-pediatric-epinephrine-auto-injector</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/epinephreine-autoinjector-5feb25.webp?t=1738794209" type="image/jpeg" medium="image" fileSize="270015">
        <media:title type="plain">Lent epinephreine autoinjector</media:title>
        <media:description type="plain">US20250025638-A1, “Auto-injector.”Assignee: Lent Innovations LLCInventors: Lent, Anne M.IPC codes: A61M 5/20; A61M 5/32Publication date: Jan. 23, 2025Earliest priority details: US2023527442, July 18, 2023</media:description>
      </media:content>
    </item>
    <item>
      <title>USC team develops minimally invasive neural recording, stimulation system</title>
      <description>
        <![CDATA[Researchers from the University of Southern California filed for protection of a thin film electrode array they developed to be implanted using endovascular methods for minimally invasive, high-resolution electrical recording and stimulation of the nervous system and other electrogenic tissue.]]>
      </description>
      <guid>http://www.bioworld.com/articles/710314</guid>
      <pubDate>Thu, 18 Jul 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/710314-usc-team-develops-minimally-invasive-neural-recording-stimulation-system</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/Patent Highlights/USC-patent-7-18.webp?t=1721342891" type="image/jpeg" medium="image" fileSize="143930">
        <media:title type="plain">“Thin film endovascular electrode array and method of fabrication.”</media:title>
        <media:description type="plain">US20240215889-A1, “Thin film endovascular electrode array and method of fabrication.”
Assignee: University of Southern California
Inventors: Meng, Ellis; Thielen, Brianna Leilani
IPC codes: A61B 5/00; A61B 5/263
Publication date: July 4, 2024
Earliest priority details: US2022436301, Dec. 30, 2022</media:description>
      </media:content>
    </item>
    <item>
      <title>Researchers develop brain implant for neural recording, stimulation</title>
      <description>
        <![CDATA[Researchers from Arizona State University and Mayo Clinic have filed for protection of wireless, battery-free brain implants which may be used in the monitoring, stimulation, and treatment of epilepsy, tumors, neurodegenerative disorders, neuroinflammatory conditions and trauma.]]>
      </description>
      <guid>http://www.bioworld.com/articles/709985</guid>
      <pubDate>Thu, 11 Jul 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/709985-researchers-develop-brain-implant-for-neural-recording-stimulation</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/wireless-brain-implant-11july24.webp?t=1720733432" type="image/jpeg" medium="image" fileSize="244931">
        <media:title type="plain">wireless brain implant</media:title>
        <media:description type="plain">WO2024119097-A1, “Brain implant devices and methods.”Assignee: Mayo Foundation for Medical Education and Research; Arizona State UniversityInventors: Benbuk, Ahmed Abed; Christen, Jennifer Blain; Gulick, Daniel; Liu, Shiyi; Moniz Garcia, Diogo P.; Quinones-Hinojosa, AlfredoIPC Codes: A61N 1/36; A61N 1/05; A61N 1/375Publication date: June 6, 2024Earliest priority details: US2022429539, Dec. 1, 2022</media:description>
      </media:content>
    </item>
    <item>
      <title>Soligenix lights the way with positive T-cell lymphoma data</title>
      <description>
        <![CDATA[Soligenix Inc. investors were extremely enthusiastic about the positive interim update for the company’s cancer therapy and light device, Hybryte, for treating for treating early stage cutaneous T-cell lymphoma. The Princeton, N.J.-based company’s stock (NASDAQ:SNGX) soared a whopping 464% before closing at a more modest but still massive of 271% increase to $7.42 each on July 9.]]>
      </description>
      <guid>http://www.bioworld.com/articles/710382</guid>
      <pubDate>Tue, 09 Jul 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/710382-soligenix-lights-the-way-with-positive-t-cell-lymphoma-data</link>
    </item>
    <item>
      <title>Masimo receives $850M to $950M offer for consumer product joint venture</title>
      <description>
        <![CDATA[Embattled Masimo Corp. disclosed it received a non-binding term sheet offering $850 million to $950 million for a potential joint venture that would include its consumer health products and the Sound United business. In an 8-K filing with the U.S. Securities and Exchange Commission, Masimo said it intends to negotiate for a higher price.]]>
      </description>
      <guid>http://www.bioworld.com/articles/709959</guid>
      <pubDate>Mon, 08 Jul 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/709959-masimo-receives-850m-to-950m-offer-for-consumer-product-joint-venture</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Hand-holding-dollar-sign-on-yellow-background.webp?t=1712180313" type="image/jpeg" medium="image" fileSize="54627">
        <media:title type="plain">Hand holding dollar sign on yellow background</media:title>
      </media:content>
    </item>
    <item>
      <title>Masimo-Politan mudslinging gets messier</title>
      <description>
        <![CDATA[The years’ long effort by activist investor Politan Capital Management LP to take control of the Masimo Corp. board of directors and oust Masimo CEO and founder Joe Kiani took a turn for the weird this week as news emerged that Masimo Chief Operating Officer Bilal Muhsin notified the board that he would step down if Kiani were pushed out.]]>
      </description>
      <guid>http://www.bioworld.com/articles/709796</guid>
      <pubDate>Fri, 05 Jul 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/709796-masimo-politan-mudslinging-gets-messier</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/deal-merger-acquisition-cancel-terminate.webp?t=1588276898" type="image/png" medium="image" fileSize="211268">
        <media:title type="plain">Hands holding torn contract</media:title>
      </media:content>
    </item>
    <item>
      <title>Ykrita enhances IP for its artificial ectopic liver device</title>
      <description>
        <![CDATA[In just its second PCT filing, Ykrita Lifesciences Private Ltd. (YLS) continues to assemble intellectual property for its development of an extracorporeal bioengineered dual-cell liver regeneration (EBDLR) system which serves as a lightweight, portable, ectopic liver device to aid in the rejuvenation of the body’s own liver and treat acute liver failure without the need for surgery.]]>
      </description>
      <guid>http://www.bioworld.com/articles/709480</guid>
      <pubDate>Wed, 19 Jun 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/709480-ykrita-enhances-ip-for-its-artificial-ectopic-liver-device</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/ykrita-ectopic-liver-device-19june24.webp?t=1718829713" type="image/jpeg" medium="image" fileSize="123455">
        <media:title type="plain">Ykrita ectopic liver device</media:title>
        <media:description type="plain">WO2024105681-A1, “Extracorporeal bioengineered dual-cell liver regeneration system (EBDLR) and bio purifier therefor.”Assignee: Ykrita Lifesciences Private Ltd.Inventors: Datey, Akshay; Gopalan, Jagadeesh; Gopasetty, MaheshIPC Codes: A61M 1/36; A61K 38/00; A01N 1/02Publication Date: May 23, 2024Earliest Priority Details: IN202241066541, Nov. 19, 2022</media:description>
      </media:content>
    </item>
    <item>
      <title>Amber Therapeutics exploring alternative uses for bioelectric device</title>
      <description>
        <![CDATA[In a departure from its focus on using implanted electrodes to treat urinary incontinence, Amber Therapeutics Ltd. has filed for protection of similar approaches to treat sexual dysfunction and pelvic pain.]]>
      </description>
      <guid>http://www.bioworld.com/articles/706912</guid>
      <pubDate>Wed, 03 Apr 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/706912-amber-therapeutics-exploring-alternative-uses-for-bioelectric-device</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/Patent Highlights/amber-therapeutics-3apr24.webp?t=1712181343" type="image/jpeg" medium="image" fileSize="103661">
        <media:title type="plain">Amber Therapeutics</media:title>
        <media:description type="plain">WO2024057025-A1, “Nerve stimulator for sexual dysfunction.”Assignee: Amber Therapeutics Ltd.Inventors: Crawley, Aidan; De Wachter, Stefan; Denison, Timothy; Knowles, CharlesIPC Codes: A61N 1/05; A61N 1/36; A61B 5/00Publication date: Mar. 21, 2024Earliest priority details: US2022375835, Sept. 15, 2022</media:description>
      </media:content>
    </item>
    <item>
      <title>White paper delves into US regulatory aspects of AI in drug, device development</title>
      <description>
        <![CDATA[While the U.S. FDA’s preclinical and clinical trial framework is generally well-suited to adapt to the use of artificial intelligence (AI) in developing new drugs, its regulatory framework for medical devices that incorporate evolving AI leaves a lot to be desired, according to Sen. Bill Cassidy (R-La.), the ranking member of the Senate Health, Education, Labor and Pension Committee.]]>
      </description>
      <guid>http://www.bioworld.com/articles/700821</guid>
      <pubDate>Thu, 07 Sep 2023 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/700821-white-paper-delves-into-us-regulatory-aspects-of-ai-in-drug-device-development</link>
    </item>
    <item>
      <title>EDEN trial shows DBS improves movement in stroke patients</title>
      <description>
        <![CDATA[A first-in-human clinical trial conducted by researchers at the Cleveland Clinic demonstrated that deep brain stimulation (DBS) applied to the dentate nucleus region of the cerebellum could help patients recover function in their upper extremities up to three years after a stroke. Results of the study were published in <em>Nature Medicine</em>.]]>
      </description>
      <guid>http://www.bioworld.com/articles/700102</guid>
      <pubDate>Fri, 25 Aug 2023 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/700102-eden-trial-shows-dbs-improves-movement-in-stroke-patients</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2023/DBS-for-stroke-6-25.webp?t=1692996708" type="image/jpeg" medium="image" fileSize="94182">
        <media:title type="plain">DBS for stroke </media:title>
        <media:description type="plain">In the EDEN trial, a single DBS lead was implanted into the cerebellum and connected to a pacemaker-like device in the upper back. Credit: Courtesy of Cleveland Clinic</media:description>
      </media:content>
    </item>
    <item>
      <title>The EC releases update on MDR-IVDR applications and certification</title>
      <description>
        <![CDATA[The European Commission’s (EC’s) Directorate-General for Health and Food Safety recently published a survey of notified bodies. This was conducted between April and May 2023, eliciting responses from all 39 notified bodies designated under the Medical Devices Regulation (MDR) and 10 Notified bodies designated under the In Vitro Diagnostic Regulation (IVDR).]]>
      </description>
      <guid>http://www.bioworld.com/articles/700116</guid>
      <pubDate>Thu, 24 Aug 2023 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/700116-the-ec-releases-update-on-mdr-ivdr-applications-and-certification</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Europe/EU-flags-at-EC-building.webp?t=1735585376" type="image/jpeg" medium="image" fileSize="146760">
        <media:title type="plain">EU flags at European Commission building</media:title>
      </media:content>
    </item>
    <item>
      <title>Divergent trial results tank Medtronic’s Symplicity Spyral at FDA advisory</title>
      <description>
        <![CDATA[Dublin-based Medtronic plc. has invested considerable resources into its renal denervation program, but the company has not completed its regulatory journey for the U.S. market just yet. Medtronic failed to persuade an FDA advisory committee of the virtues of its Symplicity Spyral device due to inconsistent results from the two major studies presented at the hearing but vowed to keep working on the application despite the sustained headwinds.]]>
      </description>
      <guid>http://www.bioworld.com/articles/700096</guid>
      <pubDate>Thu, 24 Aug 2023 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/700096-divergent-trial-results-tank-medtronics-symplicity-spyral-at-fda-advisory</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2022/11-8-Medtronic---Symplicty-Spyral-HTN.webp?t=1667946402" type="image/png" medium="image" fileSize="281053">
        <media:title type="plain">Medtronic - Symplicty Spyral HTN</media:title>
        <media:description type="plain">The Symplicity Spyral RDN</media:description>
      </media:content>
    </item>
    <item>
      <title>Safe Orthopaedics unveils promising device for vertebral compression fractures</title>
      <description>
        <![CDATA[Safe Orthopaedics SAS reported results from a biomechanical study comparing its new surgical technique Sycamore – a pedicle-anchored implant – with standalone balloon kyphoplasty. The results published in summer 2023 in the <em>Journal of Experimental Orthopaedics</em> showed a “significant increase” in compression strength with patients using Sycamore.]]>
      </description>
      <guid>http://www.bioworld.com/articles/700110</guid>
      <pubDate>Wed, 23 Aug 2023 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/700110-safe-orthopaedics-unveils-promising-device-for-vertebral-compression-fractures</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2023/Sycamore-device-from-Safe-Orthopaedics-8-23.webp?t=1692827672" type="image/jpeg" medium="image" fileSize="92006">
        <media:title type="plain">Sycamore device from Safe Orthopaedics</media:title>
        <media:description type="plain">Sycamore device from Safe Orthopaedics</media:description>
      </media:content>
    </item>
    <item>
      <title>FDA gives Levita a lift to MARS with surgery system clearance</title>
      <description>
        <![CDATA[Levita Magnetics International Corp. received uplifting news this week as the U.S. FDA cleared its magnetic-Assisted Robotic Surgery (MARS) minimally invasive surgical platform. MARS builds on the company’s first product, the Levita magnetic surgical system, by providing greater control of surgical instruments to surgeons. The platform is cleared for use in bariatric, colorectal, gallbladder and prostate surgeries.]]>
      </description>
      <guid>http://www.bioworld.com/articles/700100</guid>
      <pubDate>Wed, 23 Aug 2023 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/700100-fda-gives-levita-a-lift-to-mars-with-surgery-system-clearance</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2023/Levita_MARS_Complete-System-8-23.webp?t=1692827679" type="image/jpeg" medium="image" fileSize="222347">
        <media:title type="plain">Levita Magnetics’ MARS system</media:title>
        <media:description type="plain">Levita Magnetics’ MARS systems gains FDA clearance.</media:description>
      </media:content>
    </item>
    <item>
      <title>Recor snares supportive vote from FDA advisory panel for Paradise renal denervation device</title>
      <description>
        <![CDATA[The age of renal denervation as a treatment for hypertension may have finally arrived in the U.S. with the affirmative U.S. FDA advisory vote for the Paradise system for renal denervation by Recor Medical Inc., of Palo Alto, Calif. The 12-member advisory committee vote unanimously that the data suggested the ultrasound-based device was safe and voted 8-3 in support of the Paradise’s efficacy, an outcome that the agency may find difficult to refute, given the large public health impact of hypertension in the U.S.]]>
      </description>
      <guid>http://www.bioworld.com/articles/700095</guid>
      <pubDate>Wed, 23 Aug 2023 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/700095-recor-snares-supportive-vote-from-fda-advisory-panel-for-paradise-renal-denervation-device</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2023/Recor-Medical-Paradise-renal-denervation-catheter-8-23.webp?t=1692827673" type="image/jpeg" medium="image" fileSize="214207">
        <media:title type="plain">Recor Medicaal Paradise renal denervation catheter</media:title>
        <media:description type="plain">The Paradise renal denervation catheter. The red circle indicates heat generated from the ultrasound energy in the tissue delivering energy within the artery. The blue circle indicates active cooling from circulating water within the artery to protect the artery from heat. Credit: Recor Medical Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Tandem Diabetes secures French reimbursement for semi-closed loop system</title>
      <description>
        <![CDATA[Tandem Diabetes Care Inc. obtained reimbursement in France for its Control-IQ technology, an advanced hybrid closed loop system for patients with type 1 diabetes that uses an algorithm to automatically adjust insulin in response to predicted glucose levels.]]>
      </description>
      <guid>http://www.bioworld.com/articles/700109</guid>
      <pubDate>Tue, 22 Aug 2023 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/700109-tandem-diabetes-secures-french-reimbursement-for-semi-closed-loop-system</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2023/Tandem-Control-IQ-system-8-22-.webp?t=1692736285" type="image/jpeg" medium="image" fileSize="102802">
        <media:title type="plain">Tandem Control-IQ system</media:title>
        <media:description type="plain">Tandem Diabetes Care's Control-IQ system</media:description>
      </media:content>
    </item>
    <item>
      <title>More than 20,000 patients have found relief with Sprint PNS system</title>
      <description>
        <![CDATA[Over the last six years, more than 20,000 patients have been implanted with the Sprint PNS system to manage acute or chronic pain, SPR Therapeutics Inc. reported. The 20,000th patient was treated for low back and leg pain with the Sprint Extensa XT system, which like the company’s other systems is implanted for 60 days in a minimally invasive surgery. The system uses percutaneous peripheral nerve stimulation (PNS) to recondition the central nervous system to provide long-term, significant relief from pain.]]>
      </description>
      <guid>http://www.bioworld.com/articles/700094</guid>
      <pubDate>Tue, 22 Aug 2023 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/700094-more-than-20-000-patients-have-found-relief-with-sprint-pns-system</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2023/SPRINT-Device-Image_4clr-8.22.webp?t=1692740469" type="image/jpeg" medium="image" fileSize="65780">
        <media:title type="plain">SPR Therapeutic Inc.’s Sprint PNS system</media:title>
        <media:description type="plain">SPR Therapeutic Inc.’s Sprint PNS system</media:description>
      </media:content>
    </item>
    <item>
      <title>Magassist moves forward with ECMO in China's heart failure market </title>
      <description>
        <![CDATA[Taking a step forward in an increasingly crowded market that has long been dominated by non-Chinese players, Magassist Co. Ltd. got positive clinical results from its extracorporeal membrane oxygenation (ECMO) system Breathmo to provide support for patients with serious heart failure or lung failure, with a study showing that the system can provide pulmonary and cardiac support effectively and safely.]]>
      </description>
      <guid>http://www.bioworld.com/articles/699129</guid>
      <pubDate>Fri, 21 Jul 2023 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/699129-magassist-moves-forward-with-ecmo-in-chinas-heart-failure-market</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/Heart-and-lungs.webp?t=1596747896" type="image/png" medium="image" fileSize="429739">
        <media:title type="plain">Heart and lungs</media:title>
      </media:content>
    </item>
    <item>
      <title>Neura Robotics raises $55M to expand into the US and Japan</title>
      <description>
        <![CDATA[Neura Robotics GmbH closed a $55 million funding round that will allow the company to expand its operation into the U.S. and Japan and increase its production infrastructure in Germany amid growing demand. The company, which builds cognitive robots, has an order book which exceeds $450 million.]]>
      </description>
      <guid>http://www.bioworld.com/articles/699103</guid>
      <pubDate>Thu, 20 Jul 2023 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/699103-neura-robotics-raises-55m-to-expand-into-the-us-and-japan</link>
    </item>
    <item>
      <title>Endotheia sees positive results with single-use device for endoscopic surgery</title>
      <description>
        <![CDATA[Endotheia Inc. reported the successful completion of a first-in-human clinical trial of its steerable technology for endoscopic surgery. The single-use device integrates with standard forward-viewing gastroscopes, allowing physicians to replicate the functions of specialized duodenoscopes that are currently used in the treatment of biliary disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/699055</guid>
      <pubDate>Wed, 19 Jul 2023 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/699055-endotheia-sees-positive-results-with-single-use-device-for-endoscopic-surgery</link>
    </item>
    <item>
      <title>Quidel, Medtronic hit with class I recalls</title>
      <description>
        <![CDATA[Recalls are a fact of life in the medical technology space, and Medtronic plc and Quidel Cardiovascular Inc., have both been forced to report class I recalls. Dublin-based Medtronic announced a recall of more than 348,000 cardiac electrophysiology devices due to issues that could prevent high-voltage therapy while San Diego-based Quidel is recalling nearly 7,800 Triage cardiac panels because of a risk of false negatives for patients being assessed for an infarct.]]>
      </description>
      <guid>http://www.bioworld.com/articles/699010</guid>
      <pubDate>Tue, 18 Jul 2023 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/699010-quidel-medtronic-hit-with-class-i-recalls</link>
    </item>
    <item>
      <title>Organox raises £25M to fund US expansion, eyes IPO on Nasdaq</title>
      <description>
        <![CDATA[Organox Ltd. raised £25 million (US$33 million) in a funding round that will allow the company to expand its operations in the U.S. on the back of significantly increasing demand from transplant centers, Oern Stuge, executive chairman, at Organox told <em>BioWorld</em>. The Oxford, U.K.-based company which makes systems to preserve and transport livers for transplant is also preparing for its eventual listing on Nasdaq, he added.]]>
      </description>
      <guid>http://www.bioworld.com/articles/699006</guid>
      <pubDate>Tue, 18 Jul 2023 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/699006-organox-raises-25m-to-fund-us-expansion-eyes-ipo-on-nasdaq</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2023/Organox-metra-7-18.webp?t=1689714374" type="image/jpeg" medium="image" fileSize="212077">
        <media:title type="plain">Organox metra</media:title>
        <media:description type="plain">Organox's metra device preserves donor livers and enables assessment of the organs prior to transplantation.</media:description>
      </media:content>
    </item>
    <item>
      <title>Know what? Cognito study shows gamma therapy reduces Alzheimer’s biomarkers</title>
      <description>
        <![CDATA[A study conducted by Cognito Therapeutics Inc. demonstrated significant changes in white matter volume and myelination in patients with Alzheimer’s disease after six months of at-home, non-invasive gamma stimulation therapy in a presentation at the Alzheimer’s Association International Conference 2023.]]>
      </description>
      <guid>http://www.bioworld.com/articles/698963</guid>
      <pubDate>Mon, 17 Jul 2023 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/698963-know-what-cognito-study-shows-gamma-therapy-reduces-alzheimers-biomarkers</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2023/Cognito-headset-7-17.webp?t=1689630643" type="image/jpeg" medium="image" fileSize="64361">
        <media:title type="plain">Cognito headset</media:title>
        <media:description type="plain">Cognito’s headset delivers oscillating sound and light to stimulate the brain and slow Alzheimer’s disease progression.</media:description>
      </media:content>
    </item>
    <item>
      <title>Astek Diagnostics raises $2M for early warning UTI medical device</title>
      <description>
        <![CDATA[Astek Diagnostics Inc. has wound up a successful $2 million early stage VC funding round to support the development and launch of a medical device designed for the speedy recovery of patients suffering from urinary tract infections (UTI). The Baltimore-based startup has designed a benchtop analyzer and disposable cartridge called the Jiddu that can detect bacterial infection in urine in one hour.]]>
      </description>
      <guid>http://www.bioworld.com/articles/698637</guid>
      <pubDate>Thu, 06 Jul 2023 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/698637-astek-diagnostics-raises-2m-for-early-warning-uti-medical-device</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2023/Jiddu-device-by-Astek-Diagnostics-7-6-.webp?t=1688675275" type="image/jpeg" medium="image" fileSize="89150">
        <media:title type="plain">Jiddu device by Astek Diagnostics</media:title>
        <media:description type="plain">The Jiddu medical device by Astek Diagnostics can detect bacterial infection in urine in one hour.</media:description>
      </media:content>
    </item>
  </channel>
</rss>
